CardioFocus Snags Galvanize Therapeutics’ Electrophysiology Biz

CardioFocus, a company focused on advancing ablation treatment for cardiac arrhythmias, has acquired Galvanize Therapeutics’ electrophysiology technology division.
 
Included in the acquisition is the Centauri pulsed electric field generator, which has EU approval and is commercially available in the EU and U.K. The currently in development QuickShot catheter ablation system is also a part of the deal.
 
The Centauri system disrupts aberrant electrical heart signals in the heart that cause atrial fibrillation (AFib). It uses a novel, proprietary waveform and is compatible with several focal ablation catheters and mapping systems.
 
QuickShot—which is compatible with Centauri—has a large area focal catheter. The company said it aims to continue human trials of QuickShot in 2024.
 
The acquisition also includes a license across multiple patent families covering pulsed electric field therapies, ownership of several patent families in electrophysiology and pulsed fields, and knowledge of proprietary waveform and algorithms to minimize microbubbles and muscle stimulation.
 
CardioFocus’ portfolio also features its flagship HeartLight X3 catheter ablation tech for controlled, durable pulmonary vein isolation. HeartLight X4, expected to begin human trials in 2024, is a pulsed field ablation balloon for true single-shot pulmonary vein isolation.
 
“We look forward to welcoming Centauri users in the EU and recognize the important contribution these clinicians have made to our understanding of focal pulse field ablation. Through this acquisition we will expand our presence in Europe and the UK while supporting and growing our global HeartLight X3 and Centauri customer bases,” said CardioFocus CEO Steve Ogilvie. “We are dedicated to improving patient outcomes and optimizing clinical workflow. This acquisition strengthens our leadership position as we innovate the next generation of pulsed field technologies for both focal and true single shot ablation.”